We overcome the biggest challenge for genetic medicines: Safe and effective delivery. We developed a field-leading proprietary technology for systemic nucleic acid delivery, based on scalable non-immunogenic materials. Our patented data-driven high-throughput screening platform allows us to screen novel nanocarrier formulations at unparalleled scale. We use our cell-specific nanocarriers to develop mRNA and gene editing therapies for currently incurable diseases. Our pipeline includes immunotherapies, which we strive to advance rapidly into the clinic.